Research

Energy balance

SGLT2 inhibitor-induced glycosuria triggers a compensatory increase in energy intake (hyperphagia) that partially offsets the expected weight loss, resulting in net weight loss significantly lower than predicted by urinary glucose excretion alone.

If you take an SGLT2 inhibitor like empagliflozin, your body will naturally try to regain the calories lost in urine by making you eat more. This biological compensation significantly reduces the amount of weight you will lose compared to what the drug's mechanism suggests. To achieve significant weight loss, you cannot rely on the drug alone; you must actively implement caloric restriction to overcome this increased appetite.

GoodQualifiesHIGH confidence
Chronic glycosuria elicits an adaptive increase in energy intake... patients lost only 29 +/- 41% of the weight loss predicted by their glycosuria; the model indicated that this difference was accounted for by a 13% (IQR 12) increase in calorie intake (269 kcal/day [IQR 258])
Giulia Ferrannini et al. · Diabetes Care · 2015

Why this rating

The study uses a validated mathematical model on a substantial cohort (n=86) with long-term follow-up (90 weeks), though energy intake is modeled rather than directly measured via food diaries.

Source

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

Giulia Ferrannini et al. · Diabetes Care · 2015

DOI 10.2337/dc15-0355

cohort · n=86Cited 354×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →